Quick Takeaways
- This page summarizes Christopher B. Ehrlich's Form 4 filing for eFFECTOR Therapeutics, Inc..
- 1 reported transaction and 1 derivative row are listed below.
- Filing timestamp: 21 Feb 2024, 17:25.
Christopher B. Ehrlich - 19 Feb 2024 Form 4 Insider Report for eFFECTOR Therapeutics, Inc.
- Role
- Director
- Signature
- /s/ Michael Byrnes, Attorney-in-Fact for Christopher B. Ehrlich
- Issuer symbol
- N/A
- Transactions as of
- 19 Feb 2024
- Net transactions value
- $0
- Form type
- 4
- Filing time
- 21 Feb 2024, 17:25:25 UTC
- Previous filing
- 16 Feb 2024
- Next filing
- 27 Mar 2024
- SEC
- View on sec.gov
Quoteable Key Fact
"Christopher B. Ehrlich filed Form 4 for eFFECTOR Therapeutics, Inc. on 21 Feb 2024."
What Changed
- Previous filing in this sequence was filed on 16 Feb 2024.
- Current net transaction value: $0.
Why This Matters
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Source Evidence
Filed on Form 4
See Original Filing
Ownership activity is grounded in SEC Form 4 disclosures.
Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | EFTR | Stock Option (Right to Buy) | Award | $0 | +2,000 | $0.000000 | 2,000 | 19 Feb 2024 | Common Stock | 2,000 | $11.32 | Direct | F1 |
* An asterisk sign (*) next to the price indicates that the price is likely invalid.
Explanation of Responses:
| Id | Content |
|---|---|
| F1 | The shares subject to the option will vest in substantially equal monthly installments over 12 months, commencing on February 19, 2024, subject to the Reporting Person's continued service with the Issuer through each vesting date. |